ArticleOncotarget2016

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.

Parag P Patwardhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.